Clinical trials: Healthy Adult Immune Response
HIV Infections
Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
This study will evaluate the safety and preliminary immune response to recombinant adenoviral serotype 35 and 5 HIV-1 vaccines in HIV-uninfected adults.
- Trial name
- NCT00801697
- Testing
- DNA Vaccine, rAd35, rAd5
- Where
- 10 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
The purpose of the study is to determine the safety of and immune response to the investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.
- Trial name
- NCT00141024
- Testing
- EP HIV-1043, EP HIV-1090
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults
This study will evaluate the safety of and the body's immune response to experimental HIV vaccine regimens using different vaccine priming combination, and boosting with the vaccines NYVAC and AIDSVAX® B/E.
- Trial name
- NCT01799954
- Testing
- DNA-HIV-PT123, NYVAC-HIV-PT1, NYVAC-HIV-PT4
- Where
- Switzerland
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
Pneumonia, Bacterial
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years.
- Trial name
- NCT07428759
- Testing
- Pn-MAPS30plus, PCV20
- Where
- 2 sites in Australia
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus, SARS-CoV-2 Infection
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)
The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05633446
- Testing
- PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations)
- Where
- 2 sites in Philippines
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
HIV Infections
Phase I Study of Vaccination Schedule of Experimental HIV Vaccines
This study will test whether a vaccination schedule of experimental HIV vaccines is safe and whether it causes side effects in healthy adult volunteers.
- Trial name
- NCT00321061
- Testing
- VRC-HIVDNA016-00, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
Background: Respiratory Syncytial Virus (RSV) is a virus that infects the lungs and breathing passages. Healthy adults who are infected generally have mild cold symptoms for a week or two.
- Trial name
- NCT03049488
- Testing
- VRC-RSVRGP084-00-VP, Aluminum Hydroxide Suspension
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
The purpose of this study was to evaluate the reactogenicity, safety and immune response of a single intramuscular dose of the respiratory syncytial virus maternal (RSV MAT) vaccine in healthy non-pregnant girls 9-17 years of age…
- Trial name
- NCT05169905
- Testing
- RSV MAT vaccine, dTpa vaccine
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Adult Immune Responses to Vaccine
Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults
Background: Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02231866
- Testing
- VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP
- Where
- 3 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
The purpose of the study is to compare the safety of \& immune response to a single dose of GSK Biologicals' cell-culture based influenza vaccine 138842A with that of a US licensed, egg-based trivalent influenza vaccine [Fluarix]…
- Trial name
- NCT00693706
- Testing
- Trivalent influenza vaccine GSK 138842A, Fluarix
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Zika Infection, Zika-Specific Immune Response
Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Background: The Zika virus is passed to humans by infected mosquitos. It usually causes fever, rash, joint pain, and red eyes. Recently, some cases of microcephaly (abnormally small head) were reported in babies born to mothers…
- Trial name
- NCT02840487
- Testing
- VRC-ZKADNA085-00-VP
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults
Vaccines are one of our most effective public health tools but many who need them don't respond well and are not protected. Adjuvants boost immune responses and are commonly included in vaccine preparations.
- Trial name
- NCT02057263
- Testing
- Alendronate, Hepatitis B Vaccine
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HIV Infections
Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
The purpose of this study is to determine the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with either an experimental adenoviral vector HIV vaccine of serotype 5 or 35 in HIV uninfected…
- Trial name
- NCT00472719
- Testing
- VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
- Where
- 7 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to…
- Trial name
- NCT00192153
- Testing
- CAIV-T or TIV
- Where
- 2 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza A Virus, H5N1 Subtype, Influenza A Virus
Safety Study of Avian Flu Vaccine
This study will determine if an experimental avian flu (bird flu) vaccine is safe, whether it has side effects and if it can stimulate an immune response in people.
- Conditions
- Influenza A Virus, H5N1 Subtype, Influenza A Virus, Influenzavirus A, Orthomyxoviridae
- Trial name
- NCT00408109
- Testing
- VRC-AVIDNA036-00-VP
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults
This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of Ulmus macrocarpa water extract for immunity improvement in relatively healthy adults.
- Trial name
- NCT02414412
- Testing
- Ulmus macrocarpa water extract
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pusan National University Hospital
Influenza, Human
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
Background: Vaccines are substances used to try to create resistance or immunity to a disease and to prevent an infection. Investigators are looking into improved ways to give and test the results of different kinds of vaccines.
- Trial name
- NCT00995982
- Testing
- VRC-FLUDNA056-00VP
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gut Dysbiosis
A Clinical Study to Assess the Safety and Effectiveness of Test Product in Healthy Adult Human Subjects Having Symptoms of Gut Dysbiosis (Heart Burn, Bloating, Constipation and Gut Immunity).
This is prospective, open-label, single-arm, proof of science, clinical safety and efficacy study of MetProUltima in healthy adult human subjects having symptoms of Gut Dysbiosis (heart burn, bloating, constipation).
- Trial name
- NCT06572358
- Testing
- MetProUltima
- Where
- India
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- NovoBliss Research Pvt Ltd
HIV Infections
Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine, HIV-1 gag DNA, with and without an IL-15 DNA adjuvant (at escalating doses of 100, 500, and 1500 mcg).
- Trial name
- NCT00115960
- Testing
- HIV-1 gag DNA, IL-15 DNA adjuvant, IL-12 DNA adjuvant
- Where
- 7 sites in United States, Brazil
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults
The purpose of this study is to evaluate the safety of and immune response to an alphavirus replicon, HIV-1 subtype C gag vaccine, AVX101, in HIV uninfected adults in the United States, South Africa, and Botswana.
- Trial name
- NCT00097838
- Testing
- AVX101
- Where
- 8 sites in United States, Botswana and 1 more
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.